Pharmaceutical company Eli Lilly has reported substantial weight reductions in late-stage clinical testing for its experimental obesity medicine, retatrutide. In topline results from its Phase 3 TRIUMPH-1 trial reported in May 2026, adults with overweight or obesity who received the highest 12 mg once-weekly dose achieved an average body-weight reduction of 28.3% at 80 weeks, compared with a 2.2% reduction among participants given a placebo, according to Medscape and USA Today.

Unlike currently approved weight management therapies that target one or two metabolic hormone pathways, retatrutide is an investigational triple agonist designed to stimulate three distinct receptors simultaneously. While the trial figures mark some of the largest weight reductions recorded in pharmaceutical studies to date, medical reviewers emphasize that retatrutide remains an unapproved investigational medication in the United States and that cross-trial comparisons with existing medications carry significant limitations.

How the Triple-Agonist Mechanism Works

To understand how Eli Lilly's experimental compound differs from existing options on the American market, it helps to examine the hormones involved in regulating appetite and metabolism. First-generation modern obesity medications, such as semaglutide, mimic a single gut hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar, slows stomach emptying, and signals satiety to the brain. Dual agonists, such as Eli Lilly's currently approved tirzepatide (marketed as Zepbound for obesity), target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Retatrutide adds a third target: the glucagon receptor, according to Medscape. By acting as a triple agonist across GLP-1, GIP, and glucagon receptors, the medication aims to pair appetite suppression with an increase in energy expenditure. Prior to the Phase 3 program, an earlier Phase 2 study published in 2023 involving 338 adults with overweight or obesity found that participants taking the 12 mg dose of retatrutide experienced an average weight loss of 24.2% at 48 weeks, compared with 2.1% in the placebo group.

Breaking Down the Phase 3 TRIUMPH Results

The 2026 data from Eli Lilly's Phase 3 TRIUMPH clinical trial program illustrate that weight loss outcomes vary significantly depending on the underlying health characteristics of the patients being studied. While some coverage highlights the 28.3% average weight reduction at 80 weeks seen in TRIUMPH-1, that specific study enrolled adults with overweight or obesity and at least one weight-related condition who did not have diabetes.

In July 2026, Eli Lilly reported additional 80-week topline data from two sibling trials evaluating different patient populations. In TRIUMPH-3, which enrolled participants with severe obesity and established cardiovascular disease, the highest dose produced an average weight reduction of 22.6%, according to USA Today.

In TRIUMPH-2, which evaluated adults with overweight or obesity alongside type 2 diabetes, weight loss was lower than in the non-diabetic cohort, a pattern consistently observed across metabolic drug studies. Furthermore, secondary reports vary slightly on the exact high-dose figure for the diabetes cohort depending on the statistical analysis referenced: Medscape reports an average weight reduction of 20.8% at the highest dose versus 4.0% with placebo at 80 weeks, while Welltica notes a figure of 18.8% in a particular analysis following a September 2026 publication report. These differences highlight why clinicians scrutinize full peer-reviewed trial data and specific statistical methods—such as whether numbers reflect all assigned patients or only those who adhered strictly to treatment—rather than relying solely on company-announced topline summaries.

Comparing Retatrutide to Existing Treatments and Competitors

As pharmaceutical companies race to develop next-generation metabolic therapies, patients and clinicians are naturally comparing new data against established drugs and rival pipeline candidates. However, no completed head-to-head clinical trial has directly compared retatrutide against approved therapies like semaglutide or tirzepatide, according to Medscape. Comparing percentages across separate studies can be misleading because trials differ in length, participant demographics, baseline weights, and study design.

Even though some commentary has compared retatrutide's nearly 30% weight reduction to outcomes seen with bariatric surgery, medical commentators caution against treating the drug as a guaranteed solution for every patient. Specifically, clinical trial results in treatment-naive participants do not establish that retatrutide will reverse weight plateaus in individuals who have already been taking semaglutide or tirzepatide.

Meanwhile, competition in the pharmaceutical pipeline remains active. In a separate development reported by Reuters in October 2026, Eli Lilly announced that a different experimental combination drug outperformed its approved medication Zepbound in a direct head-to-head trial. Competitor Novo Nordisk is also advancing its own next-generation candidate, CagriSema. On October 20, 2026, CNBC reported that an analysis of roughly 2,300 women with overweight or obesity showed CagriSema drove an average weight loss of 25% at 68 weeks, compared with 3% for placebo.

Safety Profile and Side Effects

Like existing GLP-1 and dual-agonist medications, retatrutide's side effect profile is primarily centered on the digestive tract. Reported common adverse events across the studies include nausea, diarrhea, and vomiting, according to Medscape. In secondary coverage of the TRIUMPH-2 diabetes trial, Welltica reported that between 8% and 12% of participants assigned to the two highest doses discontinued treatment due to side effects, though independent reviewers note that full safety figures require verification against primary peer-reviewed publications.

Frequently Asked Questions

Are the Phase 3 TRIUMPH results published in a peer-reviewed medical journal?

While a September 2026 report indicated that findings from the TRIUMPH-2 diabetes study were published in a medical journal, the 28.3% weight reduction figure from TRIUMPH-1 was released as a company-announced topline result in May 2026. Independent medical coverage distinguishes between corporate press releases and fully published, peer-reviewed trial reports that detail complete safety and statistical analyses.

Can the 28.3% weight-loss result be expected for everyone taking the drug?

No. The 28.3% average reduction occurred specifically among adults without diabetes taking the highest 12 mg dose over 80 weeks in TRIUMPH-1. Separate Phase 3 trials showed different average outcomes for other groups at 80 weeks, including 20.8% (or 18.8% depending on the analysis) in adults with type 2 diabetes and 22.6% in adults with severe obesity and cardiovascular disease.

Has retatrutide been proven superior to Zepbound or Wegovy?

There is no completed randomized, head-to-head clinical trial comparing retatrutide directly against tirzepatide (Zepbound) or semaglutide (Wegovy) in identical patient populations over the same duration. While Eli Lilly reported in October 2026 that a separate experimental combination therapy outperformed Zepbound in a direct trial, that finding involved a different drug candidate and does not apply to retatrutide.

Sources